Crucell Intends to Delist Ordinary Shares on NYSE Euronext
15 Marzo 2011 - 4:57AM
Marketwired
Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext,
NASDAQ: CRXL) (SWISS: CRX) today announced that it has obtained the
approval of Euronext Amsterdam N.V. to terminate the listing of its
ordinary shares (Ordinary Shares) on NYSE Euronext in Amsterdam
(NYSE Euronext).
The termination of the listing of Ordinary Shares on NYSE
Euronext was approved by Euronext Amsterdam N.V. and will occur on
12 April 2011. The last trading day will be 11 April 2011.
As of the time of delisting from NYSE Euronext, the following
codes will no longer be applicable to Crucell N.V. (Crucell):
symbol "CRXL": Euronext code NL0000358562, ISIN: NL0000358562.
Crucell intends to delist the Ordinary Shares from the Swiss
Exchange (SIX) simultaneously with the delisting from NYSE
Euronext.
As previously announced on 8 March 2011, to effect the delisting
of the American Depositary Shares (ADSs) from the NASDAQ Global
Market Select (NASDAQ), Crucell intends to file a Form 25 with the
U.S. Securities and Exchange Commission (SEC). Crucell intends to
file a Form 15F with the SEC to deregister and terminate its
reporting obligations under the U.S. Securities Exchange Act of
1934, as amended. The filing of the Form 15F will precede the
delisting of the Ordinary Shares from NYSE Euronext and SIX.
Crucell reserves the right to delay or withdraw for any reason
the filing of the Form 25 and Form 15F or the delisting on NYSE
Euronext and/or SIX.
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) is a
global biopharmaceutical company focused on research development,
production and marketing of vaccines, proteins and antibodies that
prevent and/or treat infectious diseases. In 2010 alone, Crucell
distributed more than 105 million vaccine doses in more than 100
countries around the world. Crucell is one of the major suppliers
of vaccines to UNICEF and the developing world. Crucell was the
first manufacturer to launch a fully-liquid pentavalent vaccine.
Called Quinvaxem®, this innovative combination vaccine protects
against five important childhood diseases. Over 180 million doses
have been sold since its launch in 2006 in more than 50 GAVI
countries. With this innovation, Crucell has become a major partner
in protecting children in developing countries. Other products in
Crucell's core portfolio include a vaccine against hepatitis B and
a virosome- adjuvanted vaccine against influenza. Crucell also
markets travel vaccines, such as an oral anti-typhoid vaccine, an
oral cholera vaccine and the only aluminum- free hepatitis A
vaccine on the market. Crucell has a broad development pipeline,
with several product candidates based on its unique PER.C6®
production technology. Crucell licenses its PER.C6® technology and
other technologies to the biopharmaceutical industry. Important
partners and licensees include Johnson & Johnson, DSM
Biologics, sanofi-aventis, Novartis, Pfizer/Wyeth, GSK, CSL and
Merck & Co. Crucell is headquartered in Leiden, the
Netherlands, with offices in China, Indonesia, Italy, Korea,
Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam.
Crucell employs over 1300 people. For more information, please
visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that
involve inherent risks and uncertainties. We have identified a
number of important factors that may cause actual results to differ
materially from those contained in such forward-looking statements.
For information relating to these factors please refer to our Form
20-F, as filed with the US Securities and Exchange Commission on
April 7, 2010, in the section entitled 'Risk Factors' and in our
second quarter 2010 financial results, as filed with the Securities
and Exchange Commission on August 17, 2010 in the section entitled
'Risk Paragraph'. The Company prepares its financial statements
under International Financial Reporting Standards (IFRS).
PDF file: http://hugin.info/132631/R/1496941/432704.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Crucell N.V. via Thomson Reuters ONE
[HUG#1496941]
For further information please contact: Oya Yavuz Vice President
Corporate Communications & Investor Relations Tel. +31 (0)71
519 7064 Email Contact www.crucell.com
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Crucell NV ADS, Each Representing One Ordinary Share (MM) (NASDAQ:CRXL)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024